ROVI is a company committed to innovation, allowing it to safeguard its portfolio composed of over 500 patent dossiers, 408 of which have now been granted, while 96 are in the examination and evaluation phase. Currently, ROVI’s R&D projects are mainly focused on the glycomics and ISM® platforms, the latter of which is a drug release system, owned by ROVI, whose objective is to improve patient treatment adherence.

ROVI has received the support of the Ministry of Economic Affairs and Competition in its Research and Development work through the TORRES QUEVEDO programme. This programme fosters the recruitment of doctors to develop industrial research projects, experimental development or feasibility studies, in order to promote the professional career of investigators, as well as to stimulate private-sector demand for well trained personnel to undertake R&D plans and projects, and help to consolidate newly-created technological companies.

Thanks to the funding received, the staff has been reinforced through the recruitment  of two university doctors for the implementation of the R&D&I activity within the framework of the projects “Project to improve the purification process in low molecular weight heparins” y “Letrozole clinical development ISM®”, File references: PTQ-2019-010712 Y PTQ-2019-010542.